vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and CSW INDUSTRIALS, INC. (CSW). Click either name above to swap in a different company.
CSW INDUSTRIALS, INC. is the larger business by last-quarter revenue ($233.0M vs $180.9M, roughly 1.3× AVANOS MEDICAL, INC.). CSW INDUSTRIALS, INC. runs the higher net margin — 4.4% vs -0.7%, a 5.1% gap on every dollar of revenue. On growth, CSW INDUSTRIALS, INC. posted the faster year-over-year revenue change (20.3% vs 0.7%). CSW INDUSTRIALS, INC. produced more free cash flow last quarter ($22.7M vs $21.3M). Over the past eight quarters, CSW INDUSTRIALS, INC.'s revenue compounded faster (5.1% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
AVNS vs CSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $233.0M |
| Net Profit | $-1.3M | $10.3M |
| Gross Margin | 47.5% | 39.7% |
| Operating Margin | 1.4% | 7.4% |
| Net Margin | -0.7% | 4.4% |
| Revenue YoY | 0.7% | 20.3% |
| Net Profit YoY | 99.7% | -61.9% |
| EPS (diluted) | $-0.02 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $233.0M | ||
| Q3 25 | $177.8M | $277.0M | ||
| Q2 25 | $175.0M | $263.6M | ||
| Q1 25 | $167.5M | $230.5M | ||
| Q4 24 | $179.6M | $193.6M | ||
| Q3 24 | $170.4M | $227.9M | ||
| Q2 24 | $171.7M | $226.2M | ||
| Q1 24 | $166.1M | $210.9M |
| Q4 25 | $-1.3M | $10.3M | ||
| Q3 25 | $-1.4M | $40.7M | ||
| Q2 25 | $-76.8M | $40.9M | ||
| Q1 25 | $6.6M | $35.1M | ||
| Q4 24 | $-397.3M | $26.9M | ||
| Q3 24 | $4.3M | $36.1M | ||
| Q2 24 | $1.8M | $38.6M | ||
| Q1 24 | $-900.0K | $31.8M |
| Q4 25 | 47.5% | 39.7% | ||
| Q3 25 | 48.4% | 43.0% | ||
| Q2 25 | 52.6% | 43.8% | ||
| Q1 25 | 53.6% | 44.2% | ||
| Q4 24 | 54.6% | 41.4% | ||
| Q3 24 | 54.5% | 45.6% | ||
| Q2 24 | 55.7% | 47.5% | ||
| Q1 24 | 57.1% | 44.4% |
| Q4 25 | 1.4% | 7.4% | ||
| Q3 25 | 0.1% | 20.5% | ||
| Q2 25 | -42.6% | 20.8% | ||
| Q1 25 | 6.1% | 19.5% | ||
| Q4 24 | -233.0% | 15.3% | ||
| Q3 24 | 7.0% | 22.6% | ||
| Q2 24 | 3.7% | 24.3% | ||
| Q1 24 | 2.4% | 21.0% |
| Q4 25 | -0.7% | 4.4% | ||
| Q3 25 | -0.8% | 14.7% | ||
| Q2 25 | -43.9% | 15.5% | ||
| Q1 25 | 3.9% | 15.2% | ||
| Q4 24 | -221.2% | 13.9% | ||
| Q3 24 | 2.5% | 15.8% | ||
| Q2 24 | 1.0% | 17.1% | ||
| Q1 24 | -0.5% | 15.1% |
| Q4 25 | $-0.02 | $0.62 | ||
| Q3 25 | $-0.03 | $2.41 | ||
| Q2 25 | $-1.66 | $2.43 | ||
| Q1 25 | $0.14 | $2.05 | ||
| Q4 24 | $-8.64 | $1.60 | ||
| Q3 24 | $0.09 | $2.26 | ||
| Q2 24 | $0.04 | $2.47 | ||
| Q1 24 | $-0.02 | $2.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $40.2M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $1.1B |
| Total Assets | $1.1B | $2.3B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $40.2M | ||
| Q3 25 | $70.5M | $31.5M | ||
| Q2 25 | $90.3M | $38.0M | ||
| Q1 25 | $97.0M | $225.8M | ||
| Q4 24 | $107.7M | $213.8M | ||
| Q3 24 | $89.0M | $273.2M | ||
| Q2 24 | $92.2M | $18.9M | ||
| Q1 24 | $75.8M | $22.2M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | $800.1M | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | $166.0M |
| Q4 25 | $778.2M | $1.1B | ||
| Q3 25 | $778.0M | $1.1B | ||
| Q2 25 | $776.3M | $1.1B | ||
| Q1 25 | $839.4M | $1.1B | ||
| Q4 24 | $828.5M | $1.0B | ||
| Q3 24 | $1.2B | $1.0B | ||
| Q2 24 | $1.2B | $650.2M | ||
| Q1 24 | $1.2B | $615.7M |
| Q4 25 | $1.1B | $2.3B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.2B | $1.4B | ||
| Q3 24 | $1.7B | $1.4B | ||
| Q2 24 | $1.7B | $1.1B | ||
| Q1 24 | $1.7B | $1.0B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | 0.75× | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $28.9M |
| Free Cash FlowOCF − Capex | $21.3M | $22.7M |
| FCF MarginFCF / Revenue | 11.8% | 9.8% |
| Capex IntensityCapex / Revenue | 3.8% | 2.6% |
| Cash ConversionOCF / Net Profit | — | 2.81× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $162.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $28.9M | ||
| Q3 25 | $14.0M | $61.8M | ||
| Q2 25 | $6.8M | $60.6M | ||
| Q1 25 | $25.7M | $27.3M | ||
| Q4 24 | $57.9M | $11.6M | ||
| Q3 24 | $23.0M | $66.8M | ||
| Q2 24 | $27.8M | $62.7M | ||
| Q1 24 | $-8.0M | $22.4M |
| Q4 25 | $21.3M | $22.7M | ||
| Q3 25 | $7.0M | $58.7M | ||
| Q2 25 | $-4.2M | $57.7M | ||
| Q1 25 | $19.0M | $22.8M | ||
| Q4 24 | $53.1M | $8.5M | ||
| Q3 24 | $20.0M | $61.3M | ||
| Q2 24 | $21.9M | $59.6M | ||
| Q1 24 | $-12.1M | $17.5M |
| Q4 25 | 11.8% | 9.8% | ||
| Q3 25 | 3.9% | 21.2% | ||
| Q2 25 | -2.4% | 21.9% | ||
| Q1 25 | 11.3% | 9.9% | ||
| Q4 24 | 29.6% | 4.4% | ||
| Q3 24 | 11.7% | 26.9% | ||
| Q2 24 | 12.8% | 26.3% | ||
| Q1 24 | -7.3% | 8.3% |
| Q4 25 | 3.8% | 2.6% | ||
| Q3 25 | 3.9% | 1.1% | ||
| Q2 25 | 6.3% | 1.1% | ||
| Q1 25 | 4.0% | 2.0% | ||
| Q4 24 | 2.7% | 1.6% | ||
| Q3 24 | 1.8% | 2.4% | ||
| Q2 24 | 3.4% | 1.4% | ||
| Q1 24 | 2.5% | 2.3% |
| Q4 25 | — | 2.81× | ||
| Q3 25 | — | 1.52× | ||
| Q2 25 | — | 1.48× | ||
| Q1 25 | 3.89× | 0.78× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | 5.35× | 1.85× | ||
| Q2 24 | 15.44× | 1.62× | ||
| Q1 24 | — | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
